ClinicalTrials.gg
CompletedNCT03100344Updated Oct 22, 2019Results posted

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

A Phase 2 interventional study of Nemolizumab and Placebo in Atopic Dermatitis, sponsored by Galderma R&D. Completed at 67 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-22.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
7th of 14
226 · median 209
Started
2017
the only one that year
Phase 2
7 of 14
1 open now
Registered
2nd of 14
by date
Lead sponsor
12 of 14
Galderma R&D

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 2nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.

Read the detailed description

The aim of the study is to assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving topical corticosteroids, who were not adequately controlled with topical treatments.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥ 18 years (or legal age when higher)
  • Chronic AD, that has been present for at least 2 years before the visit
  • Eczema Area and Severity Index (EASI) score ≥12
  • Investigator Global Assessment (IGA) score ≥ 3
  • AD involvement ≥ 10% of Body Surface Area (BSA)
  • Severe pruritus on at least 3 of the last 7 days before the visit
  • Documented recent history (within 6 months before the visit) of inadequate response to topical medications
  • Female subjects must fulfill one of the criteria below:

    • Female subjects of non-
    • Female subjects of childbearing potential who agree to a true abstinence or to use an effective or highly effective method of throughout the clinical trial and for 120 days after the last study drug administration

Exclusion criteria

Exclusion Criteria:

  • Body weight \< 45 kg
  • subjects with a medical history of asthma requiring hospitalization in the last 12 months before screening visit and/or whose asthma has not been well-controlled during the last 3 months before the screening visit and/or Peak Expiratory Flow (PEF) \<80% of the predicted value
  • Cutaneous bacterial or viral infection within 1 week before the screening visit or during the run-in period
  • Infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 1 week before the screening visit or during the run-in period
  • History of intolerance to low or mid potency TCS or for whom TCS is not advisable
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    Group 1

    Nemolizumab (low dose)

    Drug: Nemolizumab

  • Experimental
    Group 2

    Nemolizumab (medium dose)

    Drug: Nemolizumab

  • Experimental
    Group 3

    Nemolizumab (high dose)

    Drug: Nemolizumab

  • Placebo comparator
    Group 4

    Nemolizumab placebo

    Drug: Placebo

Interventions

  • Injection every 4 weeks during 24 weeks (last injection at week 20)

  • DrugPlacebo

    Injection every 4 weeks during 24 weeks (last injection at week 20)

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24

    EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24

    The 4-point pruritus categorical scale was provided in their local language for the participants to report the intensity of their pruritus. Overall itching was scored as 0 for absence of pruritus and 3 for severe pruritus (bothersome itching/scratching that disturbs sleep). Higher scores indicate worse outcome.

    Time frame: Week 24

  2. Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

    Time frame: From Week 1 to Week 24

  3. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24

    SCORAD ranges from 0 to 103 and has three components: extent (body surface area \[BSA\]), signs, and symptoms of AD. The severity of the 6 signs of AD (erythema/darkening, edema/papulation, oozing/crusting, excoriation, lichenification/prurigo and dryness), was assessed, each on a scale ranging from 0 (none) to 3 (severe).The component of extent corresponded to the extent of BSA affected by atopic dermatitis.The BSA involvement of AD was assessed for each part of the body (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]), and was reported as a percentage of all major body sections combined. Participants were also asked to evaluate their symptoms of pruritus and sleep loss (average for the last 3 days/nights), each evaluated on a Visual analog scale (VAS) from 0 to 10. Higher scores indicate worse outcome.

    Time frame: Baseline, Week 24

  4. Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24

    SCORAD ranges from 0 to 103 and has three components: extent (body surface area \[BSA\]), signs, and symptoms of AD. The severity of the 6 signs of AD (erythema/darkening, edema/papulation, oozing/crusting, excoriation, lichenification/prurigo and dryness), was assessed, each on a scale ranging from 0 (none) to 3 (severe).The component of extent corresponded to the extent of BSA affected by atopic dermatitis.The BSA involvement of AD was assessed for each part of the body (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]), and was reported as a percentage of all major body sections combined. Participants were also asked to evaluate their symptoms of pruritus and sleep loss (average for the last 3 days/nights), each evaluated on a Visual analog scale (VAS) from 0 to 10. Higher scores indicate worse outcome.

    Time frame: Baseline, Week 24

  5. Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24

    The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night?: On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.

    Time frame: Baseline, Week 24

  6. Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24

    The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night?: On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.

    Time frame: Baseline, Week 24

  7. Number of Participants Achieving Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) at Each Timepoint up to Week 24

    IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used to evaluate the global severity of AD. Higher scores indicate worse outcome.

    Time frame: From Week 1 to Week 24

  8. Number of Participants With Eczema Area and Severity Index (EASI)-50 (Defined as Achieving 50% Reduction From Baseline in EASI Score) at Each Visit up to Week 24

    EASI is a composite score ranging from 0 to 72. The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

    Time frame: From Week 1 to Week 24

  9. Number of Participants With Eczema Area and Severity Index (EASI)-75 (Defined as Achieving 75% Reduction From Baseline in EASI Score) at Each Visit up to Week 24

    EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

    Time frame: From Week 1 to Week 24

  10. Number of Participants With Eczema Area and Severity Index (EASI)-90 (Defined as Achieving 90% Reduction From Baseline in EASI Score) at Each Visit up to Week 24

    EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

    Time frame: From Week 1 to Week 24

  11. Number of Participants Achieving Investigator Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) and a Reduction of ≥2 Points at Each Visit up to Week 24

    IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used to evaluate the global severity of AD. Higher scores indicate worse outcome.

    Time frame: Week 1 to Week 24

  12. Percentage Change From Baseline in Eczema Area and Severity Index (EASI) at Each Visit up to Week 24

    EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

    Time frame: From Baseline to Week 24

  13. Percentage Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

    Time frame: At baseline and Week 24

  14. Number of Participants With Adverse Events

    To evaluate the safety of nemolizumab in participants with moderate-to-severe AD

    Time frame: From screening to Follow-up visit (Week 32)/Early termination visit

  15. Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24

    Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

    Time frame: Baseline to Week 24

  16. Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24

    Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For average itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

    Time frame: Baseline to Week 24

  17. Percentage Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24

    Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For average itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

    Time frame: Baseline to Week 24

07

Results

Posted Oct 22, 2019

Participant flow

This study was conducted at 57 investigational sites in Australia, Canada, Germany, France, Poland and the United States.

Participant flow — Overall Study
MilestonePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Started57555757
Completed43445045
Not completed1411712
Withdrew: Adverse event0323
Withdrew: Lack of efficacy2000
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject10748
Withdrew: Lost to follow-up1111

Outcome measures

PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24

EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percentage change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24
percentage changePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24-58.4 ± 31.99-72.2 ± 25.96-73.4 ± 29.67-69.2 ± 31.06
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward-Rogers · p = 0.051 · Mean difference of percentage changes: -13.6 · 95% CI -27.3 to 0.0
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = 0.016 · Mean difference of percentage changes: -16.7 · 95% CI -30.2 to -3.2
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.322 · Mean difference of percentage changes: -6.8 · 95% CI -20.5 to 6.8
SecondaryNumber of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24

The 4-point pruritus categorical scale was provided in their local language for the participants to report the intensity of their pruritus. Overall itching was scored as 0 for absence of pruritus and 3 for severe pruritus (bothersome itching/scratching that disturbs sleep). Higher scores indicate worse outcome.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24
ParticipantsPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 2413233120
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.034 · Mean difference (final values): 18.9 · 95% CI 2.0 to 35.8
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 31.4 · 95% CI 14.7 to 48.2
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.154 · Mean difference (final values): 12.2 · 95% CI -4.2 to 28.6
SecondaryNumber of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

Time frame:
From Week 1 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24
ParticipantsPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 139106
Week 26192117
Week 44192722
Week 811223626
Week 1213263824
Week 1612303925
Week 2013273427
Week 2414252824
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.062 · Mean difference (final values): 10.9 · 95% CI -0.4 to 22.2
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.042 · Mean difference (final values): 12.2 · 95% CI 0.8 to 23.6
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.307 · Mean difference (final values): 5.2 · 95% CI -4.7 to 15.0
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.003 · Mean difference (final values): 24.0 · 95% CI 9.3 to 38.7
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.001 · Mean difference (final values): 26.2 · 95% CI 11.4 to 40.9
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.011 · Mean difference (final values): 19.0 · 95% CI 4.9 to 33.1
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 27.6 · 95% CI 13.5 to 41.7
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 40.3 · 95% CI 25.7 to 54.8
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 31.6 · 95% CI 17.4 to 45.8
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.018 · Mean difference (final values): 20.6 · 95% CI 4.2 to 37.1
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = <0001 · Mean difference (final values): 43.7 · 95% CI 27.6 to 59.9
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.003 · Mean difference (final values): 26.1 · 95% CI 9.7 to 42.6
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.007 · Mean difference (final values): 24.4 · 95% CI 7.3 to 41.4
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 43.6 · 95% CI 27.4 to 59.9
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.030 · Mean difference (final values): 19.1 · 95% CI 2.4 to 35.9
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 33.3 · 95% CI 16.4 to 50.2
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 47.2 · 95% CI 31.2 to 63.2
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.010 · Mean difference (final values): 22.8 · 95% CI 6.1 to 39.4
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.004 · Mean difference (final values): 26.3 · 95% CI 9.2 to 43.5
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 36.7 · 95% CI 20.1 to 53.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.007 · Mean difference (final values): 24.5 · 95% CI 7.6 to 41.4
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.022 · Mean difference (final values): 20.9 · 95% CI 3.6 to 38.1
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.007 · Mean difference (final values): 24.3 · 95% CI 7.4 to 41.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.050 · Mean difference (final values): 17.4 · 95% CI 0.4 to 34.4
SecondaryPercent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24

SCORAD ranges from 0 to 103 and has three components: extent (body surface area \[BSA\]), signs, and symptoms of AD. The severity of the 6 signs of AD (erythema/darkening, edema/papulation, oozing/crusting, excoriation, lichenification/prurigo and dryness), was assessed, each on a scale ranging from 0 (none) to 3 (severe).The component of extent corresponded to the extent of BSA affected by atopic dermatitis.The BSA involvement of AD was assessed for each part of the body (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]), and was reported as a percentage of all major body sections combined. Participants were also asked to evaluate their symptoms of pruritus and sleep loss (average for the last 3 days/nights), each evaluated on a Visual analog scale (VAS) from 0 to 10. Higher scores indicate worse outcome.

Time frame:
Baseline, Week 24
Reported as:
Mean · Percentage change
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24
Percentage changePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24-42.6 ± 28.25-60.8 ± 25.04-62.5 ± 25.37-55.9 ± 25.85
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.017 · Mean difference of percentage changes: -14.4 · 95% CI -26.2 to -2.7
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.058 · Mean difference of percentage changes: -11.3 · 95% CI -23.1 to 0.4
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -20.0 · 95% CI -31.6 to -8.3
SecondaryAbsolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24

SCORAD ranges from 0 to 103 and has three components: extent (body surface area \[BSA\]), signs, and symptoms of AD. The severity of the 6 signs of AD (erythema/darkening, edema/papulation, oozing/crusting, excoriation, lichenification/prurigo and dryness), was assessed, each on a scale ranging from 0 (none) to 3 (severe).The component of extent corresponded to the extent of BSA affected by atopic dermatitis.The BSA involvement of AD was assessed for each part of the body (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]), and was reported as a percentage of all major body sections combined. Participants were also asked to evaluate their symptoms of pruritus and sleep loss (average for the last 3 days/nights), each evaluated on a Visual analog scale (VAS) from 0 to 10. Higher scores indicate worse outcome.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24
units on a scalePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24-27.9 ± 19.61-40.1 ± 19.19-40.6 ± 17.22-36.1 ± 16.56
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.016 · Mean difference of absolute changes: -9.6 · 95% CI -17.5 to -1.8
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = 0.001 · Mean difference of absolute changes: -12.8 · 95% CI -20.6 to -5.1
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.058 · Mean difference of absolute changes: -7.6 · 95% CI -15.4 to 0.3
SecondaryPercent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24

The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night?: On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.

Time frame:
Baseline, Week 24
Reported as:
Mean · Percentage change
Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24
Percentage changePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24-50.7 ± 33.52-75.4 ± 27.64-76.2 ± 23.60-74.9 ± 29.39
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -24.5 · 95% CI -37.8 to -11.2
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -31.7 · 95% CI -44.9 to -18.6
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -25.1 · 95% CI -38.4 to -11.8
SecondaryAbsolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24

The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night?: On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24
units on a scalePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24-3.9 ± 2.74-6.2 ± 2.34-5.7 ± 2.51-5.8 ± 2.62
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference of absolute changes: -2.0 · 95% CI -3.1 to -1.0
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of absolute changes: -2.3 · 95% CI -3.4 to -1.3
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of absolute changes: -1.9 · 95% CI -3.0 to -0.9
SecondaryNumber of Participants Achieving Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) at Each Timepoint up to Week 24

IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used to evaluate the global severity of AD. Higher scores indicate worse outcome.

Time frame:
From Week 1 to Week 24
Reported as:
Count of participants · Participants
Number of Participants Achieving Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) at Each Timepoint up to Week 24
ParticipantsPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 11120
Week 22141
Week 42197
Week 8231011
Week 12661515
Week 16791915
Week 209111914
Week 2412142113
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.970 · Mean difference (final values): 0.1 · 95% CI -4.9 to 5.1
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.574 · Mean difference (final values): 1.7 · 95% CI -4.1 to 7.5
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.311 · Mean difference (final values): -1.8 · 95% CI -5.2 to 1.7
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.598 · Mean difference (final values): 4.2 · 95% CI -11.3 to 19.8
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.066 · Mean difference (final values): 15.5 · 95% CI -0.4 to 31.4
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.826 · Mean difference (final values): 1.7 · 95% CI -13.5 to 16.9
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.558 · Mean difference (final values): -1.8 · 95% CI -7.7 to 4.1
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.413 · Mean difference (final values): 3.4 · 95% CI -4.7 to 11.6
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.543 · Mean difference (final values): -1.8 · 95% CI -7.7 to 4.0
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.583 · Mean difference (final values): -1.7 · 95% CI -7.6 to 4.2
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.028 · Mean difference (final values): 12.2 · 95% CI 1.8 to 22.5
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.087 · Mean difference (final values): 8.7 · 95% CI -0.9 to 18.3
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.632 · Mean difference (final values): 1.9 · 95% CI -5.6 to 9.4
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.016 · Mean difference (final values): 14.0 · 95% CI 3.1 to 24.8
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.009 · Mean difference (final values): 15.8 · 95% CI 4.5 to 27.0
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.974 · Mean difference (final values): 0.2 · 95% CI -11.2 to 11.6
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.031 · Mean difference (final values): 15.6 · 95% CI 1.8 to 29.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.032 · Mean difference (final values): 13.9 · 95% CI -0.3 to 28.2
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.553 · Mean difference (final values): 4.0 · 95% CI -9.0 to 16.9
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.008 · Mean difference (final values): 20.9 · 95% CI 6.1 to 35.8
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.061 · Mean difference (final values): 13.9 · 95% CI -0.3 to 28.2
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.585 · Mean difference (final values): 4.0 · 95% CI -10.1 to 18.0
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.032 · Mean difference (final values): 17.4 · 95% CI 2.0 to 32.8
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.254 · Mean difference (final values): 8.6 · 95% CI -5.9 to 23.1
SecondaryNumber of Participants With Eczema Area and Severity Index (EASI)-50 (Defined as Achieving 50% Reduction From Baseline in EASI Score) at Each Visit up to Week 24

EASI is a composite score ranging from 0 to 72. The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

Time frame:
From Week 1 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Eczema Area and Severity Index (EASI)-50 (Defined as Achieving 50% Reduction From Baseline in EASI Score) at Each Visit up to Week 24
ParticipantsPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 1461211
Week 28181821
Week 414222924
Week 815263131
Week 1220303630
Week 1621303432
Week 2023323833
Week 2425333831
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.487 · Mean difference (final values): 3.8 · 95% CI -6.8 to 14.3
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.033 · Mean difference (final values): 14.0 · 95% CI 1.6 to 26.5
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.053 · Mean difference (final values): 12.0 · 95% CI 0.2 to 23.8
  • Placebo · Cochran-Mantel-Haenszel · p = 0.021 · Mean difference (final values): 18.5 · 95% CI 3.2 to 33.8
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.027 · Mean difference (final values): 17.4 · 95% CI 2.4 to 32.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.006 · Mean difference (final values): 22.7 · 95% CI 7.3 to 38.1
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.086 · Mean difference (final values): 15.2 · 95% CI -1.7 to 32.2
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.004 · Mean difference (final values): 26.2 · 95% CI 9.3 to 43.1
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.050 · Mean difference (final values): 17.3 · 95% CI 0.5 to 34.2
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.023 · Mean difference (final values): 20.7 · 95% CI 3.3 to 38.1
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.002 · Mean difference (final values): 27.9 · 95% CI 10.7 to 45.0
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.002 · Mean difference (final values): 27.9 · 95% CI 10.7 to 45.0
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.041 · Mean difference (final values): 19.3 · 95% CI 1.3 to 37.3
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.003 · Mean difference (final values): 27.9 · 95% CI 10.4 to 45.4
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.063 · Mean difference (final values): 17.3 · 95% CI -0.5 to 35.2
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.064 · Mean difference (final values): 17.6 · 95% CI -0.4 to 35.6
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.016 · Mean difference (final values): 22.6 · 95% CI 4.9 to 40.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.041 · Mean difference (final values): 19.1 · 95% CI 1.3 to 36.9
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.064 · Mean difference (final values): 17.6 · 95% CI -0.4 to 35.6
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.005 · Mean difference (final values): 26.0 · 95% CI 8.6 to 43.4
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.064 · Mean difference (final values): 17.2 · 95% CI -0.6 to 35.0
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.094 · Mean difference (final values): 15.9 · 95% CI -2.0 to 33.8
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.014 · Mean difference (final values): 22.4 · 95% CI 5.1 to 39.6
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.273 · Mean difference (final values): 10.2 · 95% CI -7.7 to 28.0
SecondaryNumber of Participants With Eczema Area and Severity Index (EASI)-75 (Defined as Achieving 75% Reduction From Baseline in EASI Score) at Each Visit up to Week 24

EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

Time frame:
From Week 1 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Eczema Area and Severity Index (EASI)-75 (Defined as Achieving 75% Reduction From Baseline in EASI Score) at Each Visit up to Week 24
ParticipantsPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 12233
Week 245612
Week 4371215
Week 87102115
Week 1210152521
Week 1611182821
Week 2016212521
Week 2415202625
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.979 · Mean difference (final values): 0.1 · 95% CI -6.8 to 7.0
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.668 · Mean difference (final values): 1.6 · 95% CI -5.8 to 9.0
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.658 · Mean difference (final values): 1.7 · 95% CI -5.8 to 9.2
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.690 · Mean difference (final values): 2.1 · 95% CI -8.0 to 12.2
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.521 · Mean difference (final values): 3.4 · 95% CI -6.9 to 13.7
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.033 · Mean difference (final values): 14.0 · 95% CI 1.5 to 26.5
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.172 · Mean difference (final values): 7.4 · 95% CI -3.1 to 18.0
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.014 · Mean difference (final values): 15.7 · 95% CI 3.7 to 27.7
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.002 · Mean difference (final values): 21.0 · 95% CI 8.2 to 33.9
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.404 · Mean difference (final values): 5.6 · 95% CI -7.5 to 18.8
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.003 · Mean difference (final values): 24.5 · 95% CI 9.4 to 39.6
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.059 · Mean difference (final values): 14.1 · 95% CI -0.1 to 28.2
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.222 · Mean difference (final values): 9.7 · 95% CI -5.6 to 25.0
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.003 · Mean difference (final values): 26.1 · 95% CI 10.0 to 42.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.22 · Mean difference (final values): 19.1 · 95% CI 3.3 to 35.0
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.111 · Mean difference (final values): 13.3 · 95% CI -2.8 to 29.3
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 29.6 · 95% CI 13.2 to 46.0
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.040 · Mean difference (final values): 17.4 · 95% CI 1.3 to 33.6
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.262 · Mean difference (final values): 10.1 · 95% CI -7.3 to 27.4
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.327 · Mean difference (final values): 8.7 · 95% CI -8.4 to 25.7
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.083 · Mean difference (final values): 15.7 · 95% CI -1.7 to 33.1
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.255 · Mean difference (final values): 10.1 · 95% CI -7.0 to 27.2
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.034 · Mean difference (final values): 19.0 · 95% CI 2.2 to 35.9
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.053 · Mean difference (final values): 17.4 · 95% CI 0.3 to 34.6
SecondaryNumber of Participants With Eczema Area and Severity Index (EASI)-90 (Defined as Achieving 90% Reduction From Baseline in EASI Score) at Each Visit up to Week 24

EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

Time frame:
From Week 1 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Eczema Area and Severity Index (EASI)-90 (Defined as Achieving 90% Reduction From Baseline in EASI Score) at Each Visit up to Week 24
ParticipantsPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 11121
Week 22022
Week 42143
Week 813116
Week 12471314
Week 165101912
Week 206131814
Week 246131713
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.970 · Mean difference (final values): 0.1 · 95% CI -4.9 to 5.1
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.574 · Mean difference (final values): 1.7 · 95% CI -4.1 to 7.5
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.985 · Mean difference (final values): -0.0 · 95% CI -4.8 to 4.8
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.154 · Mean difference (final values): -3.6 · 95% CI -8.4 to 1.2
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.978 · Mean difference (final values): -0.1 · 95% CI -6.8 to 6.6
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.978 · Mean difference (final values): -0.1 · 95% CI -6.8 to 6.6
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.602 · Mean difference (final values): -1.6 · 95% CI -7.5 to 4.3
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.413 · Mean difference (final values): 3.4 · 95% CI -4.5 to 11.4
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.658 · Mean difference (final values): 1.7 · 95% CI -5.7 to 9.1
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.307 · Mean difference (final values): 3.6 · 95% CI -3.2 to 10.3
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.002 · Mean difference (final values): 17.3 · 95% CI 6.9 to 27.8
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.054 · Mean difference (final values): 8.7 · 95% CI 0.1 to 17.4
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.325 · Mean difference (final values): 5.6 · 95% CI -5.4 to 16.5
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.019 · Mean difference (final values): 15.6 · 95% CI 3.1 to 28.1
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.011 · Mean difference (final values): 17.5 · 95% CI 4.5 to 30.5
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.153 · Mean difference (final values): 9.2 · 95% CI -3.2 to 21.7
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.001 · Mean difference (final values): 24.4 · 95% CI 10.3 to 38.4
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.069 · Mean difference (final values): 12.2 · 95% CI -0.7 to 25.1
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.070 · Mean difference (final values): 12.9 · 95% CI -0.8 to 26.6
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.006 · Mean difference (final values): 20.9 · 95% CI 6.5 to 35.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.052 · Mean difference (final values): 14.0 · 95% CI 0.3 to 27.7
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.069 · Mean difference (final values): 12.8 · 95% CI -0.7 to 26.3
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.011 · Mean difference (final values): 19.1 · 95% CI 4.9 to 33.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.083 · Mean difference (final values): 12.2 · 95% CI -1.3 to 25.7
SecondaryNumber of Participants Achieving Investigator Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) and a Reduction of ≥2 Points at Each Visit up to Week 24

IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used to evaluate the global severity of AD. Higher scores indicate worse outcome.

Time frame:
Week 1 to Week 24
Reported as:
Count of participants · Participants
Number of Participants Achieving Investigator Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) and a Reduction of ≥2 Points at Each Visit up to Week 24
ParticipantsPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 11120
Week 22141
Week 42197
Week 8231011
Week 12661515
Week 16791915
Week 209111914
Week 2412142113
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.970 · Mean difference (final values): 0.1 · 95% CI -4.9 to 5.1
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.574 · Mean difference (final values): 1.7 · 95% CI -4.1 to 7.5
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.311 · Mean difference (final values): -1.8 · 95% CI -5.2 to 1.7
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.558 · Mean difference (final values): -1.8 · 95% CI -7.7 to 4.1
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.413 · Mean difference (final values): 3.4 · 95% CI -4.7 to 11.6
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.543 · Mean difference (final values): -1.8 · 95% CI -7.7 to 4.0
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.583 · Mean difference (final values): -1.7 · 95% CI -7.6 to 4.2
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.028 · Mean difference (final values): 12.2 · 95% CI 1.8 to 22.5
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.087 · Mean difference (final values): 8.7 · 95% CI -0.9 to 18.3
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.632 · Mean difference (final values): 1.9 · 95% CI -5.6 to 9.4
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.016 · Mean difference (final values): 14.0 · 95% CI 3.1 to 24.8
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.009 · Mean difference (final values): 15.8 · 95% CI 4.5 to 27.0
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.974 · Mean difference (final values): 0.2 · 95% CI -11.2 to 11.6
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.031 · Mean difference (final values): 15.6 · 95% CI 1.8 to 29.3
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.032 · Mean difference (final values): 15.6 · 95% CI 1.8 to 29.5
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.553 · Mean difference (final values): 4.0 · 95% CI -9.0 to 16.9
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.008 · Mean difference (final values): 20.9 · 95% CI 6.1 to 35.8
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.061 · Mean difference (final values): 13.9 · 95% CI -0.3 to 28.2
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.585 · Mean difference (final values): 4.0 · 95% CI -10.1 to 18.0
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.032 · Mean difference (final values): 17.4 · 95% CI 2.0 to 32.8
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.254 · Mean difference (final values): 8.6 · 95% CI -5.9 to 23.1
  • Placebo vs Nemolizumab (10 mg) · Cochran-Mantel-Haenszel · p = 0.598 · Mean difference (final values): 4.2 · 95% CI -11.3 to 19.8
  • Placebo vs Nemolizumab (30 mg) · Cochran-Mantel-Haenszel · p = 0.066 · Mean difference (final values): 15.5 · 95% CI -0.4 to 31.4
  • Placebo vs Nemolizumab (90 mg) · Cochran-Mantel-Haenszel · p = 0.826 · Mean difference (final values): 1.7 · 95% CI -13.5 to 16.9
SecondaryPercentage Change From Baseline in Eczema Area and Severity Index (EASI) at Each Visit up to Week 24

EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.

Time frame:
From Baseline to Week 24
Reported as:
Mean · Percentage of change
Percentage Change From Baseline in Eczema Area and Severity Index (EASI) at Each Visit up to Week 24
Percentage of changePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 1-12.4 ± 24.32-22.7 ± 23.54-29.3 ± 31.44-28.6 ± 25.52
Week 2-24.8 ± 29.16-34.9 ± 27.70-40.1 ± 26.96-40.1 ± 32.83
Week 4-26.5 ± 33.45-40.3 ± 28.36-46.7 ± 38.49-41.8 ± 41.57
Week 8-28.6 ± 36.85-42.0 ± 38.15-51.7 ± 47.73-49.9 ± 37.21
Week 12-43.3 ± 35.22-58.5 ± 28.16-64.1 ± 33.92-56.7 ± 37.25
Week 16-47.6 ± 32.09-59.1 ± 33.09-72.2 ± 27.59-61.8 ± 41.62
Week 20-57.3 ± 31.66-67.2 ± 35.18-71.6 ± 29.39-70.9 ± 27.07
Week 24-58.4 ± 31.99-72.2 ± 25.96-73.4 ± 29.67-69.2 ± 31.06
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward-Rogers · p = 0.049 · Mean difference of percentage changes: -10.0 · 95% CI -20.0 to 0.0
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -16.9 · 95% CI -26.7 to -7.0
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.002 · Mean difference of percentage changes: -15.7 · 95% CI -25.6 to -5.8
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.084 · Mean difference of percentage changes: -9.8 · 95% CI -20.9 to 1.3
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = 0.004 · Mean difference of percentage changes: -16.2 · 95% CI -27.2 to -5.2
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.008 · Mean difference of percentage changes: -14.8 · 95% CI -25.8 to -3.8
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.044 · Mean difference of percentage changes: -14.0 · 95% CI -27.5 to -0.4
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = 0.002 · Mean difference of percentage changes: -21.1 · 95% CI -34.7 to -7.6
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.026 · Mean difference of percentage changes: -15.3 · 95% CI -28.8 to -1.8
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.062 · Mean difference of percentage changes: -14.8 · 95% CI -30.2 to 0.7
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = 0.003 · Mean difference of percentage changes: -23.4 · 95% CI -38.9 to -7.9
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.009 · Mean difference of percentage changes: -20.6 · 95% CI -36.0 to -5.2
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.022 · Mean difference of percentage changes: -15.9 · 95% CI -29.4 to -2.3
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -23.7 · 95% CI -37.1 to -10.2
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.032 · Mean difference of percentage changes: -14.7 · 95% CI -28.1 to -1.3
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.070 · Mean difference of percentage changes: -13.7 · 95% CI -28.6 to 1.1
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = 0.002 · Mean difference of percentage changes: -23.7 · 95% CI -38.5 to -8.9
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.154 · Mean difference of percentage changes: -10.7 · 95% CI -25.6 to 4.1
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.090 · Mean difference of percentage changes: -12.1 · 95% CI -26.0 to 1.9
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = 0.024 · Mean difference of percentage changes: -15.9 · 95% CI -29.7 to -2.1
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.180 · Mean difference of percentage changes: -9.5 · 95% CI -23.4 to 4.4
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.051 · Mean difference of percentage changes: -13.6 · 95% CI -27.3 to 0.0
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = 0.016 · Mean difference of percentage changes: -16.7 · 95% CI -30.2 to -3.2
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.322 · Mean difference of percentage changes: -6.8 · 95% CI -20.5 to 6.8
SecondaryPercentage Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

Time frame:
At baseline and Week 24
Reported as:
Mean · percentage of change
Percentage Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24
percentage of changePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 1-9.8 ± 18.47-22.6 ± 21.76-25.5 ± 30.15-19.8 ± 21.16
Week 2-12.9 ± 23.97-36.9 ± 27.34-42.1 ± 23.91-37.6 ± 32.29
Week 4-16.3 ± 23.77-38.7 ± 30.25-51.8 ± 26.87-45.7 ± 32.64
Week 8-23.0 ± 23.88-48.2 ± 28.82-61.5 ± 24.16-58.0 ± 28.63
Week 12-28.2 ± 28.83-58.0 ± 28.99-68.7 ± 25.04-56.4 ± 29.81
Week 16-36.2 ± 30.25-61.4 ± 28.62-71.7 ± 22.53-63.7 ± 33.07
Week 20-38.0 ± 30.11-64.6 ± 28.62-69.9 ± 26.30-69.7 ± 28.47
Week 24-42.2 ± 31.66-65.8 ± 29.94-66.9 ± 38.60-68.2 ± 26.88
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.012 · Mean difference of percentage changes: -10.9 · 95% CI -19.4 to -2.4
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -15.4 · 95% CI -23.8 to -7.1
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = 0.029 · Mean difference of percentage changes: -9.4 · 95% CI -17.8 to -0.9
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -21.8 · 95% CI -32.0 to -11.6
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -29.1 · 95% CI -39.1 to -19.1
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -23.8 · 95% CI -34.0 to -13.6
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -21.3 · 95% CI -32.1 to -10.5
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -34.8 · 95% CI -45.5 to -24.2
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -30.7 · 95% CI -41.6 to -19.9
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -22.9 · 95% CI -33.2 to -12.6
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -37.3 · 95% CI -47.4 to -27.2
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -34.1 · 95% CI -44.4 to -23.8
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -24.1 · 95% CI -35.6 to -12.5
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -38.4 · 95% CI -49.7 to -27.2
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -30.2 · 95% CI -41.7 to -18.7
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -20.9 · 95% CI -32.8 to -8.9
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -34.3 · 95% CI -46.0 to -22.6
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -28.7 · 95% CI -40.7 to -16.8
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.001 · Mean difference of percentage changes: -21.1 · 95% CI -33.7 to -8.4
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -29.7 · 95% CI -42.1 to -17.3
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -27.9 · 95% CI -40.6 to -15.2
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = 0.002 · Mean difference of percentage changes: -22.4 · 95% CI -36.1 to -8.6
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -31.5 · 95% CI -44.9 to -18.0
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -30.0 · 95% CI -43.8 to -16.2
SecondaryNumber of Participants With Adverse Events

To evaluate the safety of nemolizumab in participants with moderate-to-severe AD

Time frame:
From screening to Follow-up visit (Week 32)/Early termination visit
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Subjects with treatment-emergent SAEs1322
Treatment-emergent AEs (TEAE) with fatal outcome0100
Subjects with TEAE leading to temporary study drug0121
Subjects with TEAE leading to permanent study drug4427
Subjects with TEAE leading to study withdrawal0323
Subjects with at least 1 TEAE43474748
Subjects with severe TEAEs6352
SecondaryAbsolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24

Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

Time frame:
Baseline to Week 24
Reported as:
Mean · units on a scale
Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24
units on a scalePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 1-0.9 ± 1.38-2.0 ± 1.96-2.3 ± 1.89-1.7 ± 1.66
Week 2-1.2 ± 1.82-3.1 ± 2.34-3.4 ± 1.96-3.3 ± 2.56
Week 4-1.4 ± 1.84-3.4 ± 2.62-4.2 ± 2.21-3.8 ± 2.73
Week 8-1.9 ± 1.94-4.1 ± 2.58-5.0 ± 2.14-4.7 ± 2.54
Week 12-2.3 ± 2.44-4.9 ± 2.45-5.6 ± 2.29-4.7 ± 2.66
Week 16-2.9 ± 2.55-5.2 ± 2.34-5.8 ± 2.25-5.1 ± 2.77
Week 20-3.1 ± 2.52-5.4 ± 2.61-5.9 ± 2.22-5.4 ± 2.66
Week 24-3.5 ± 2.65-5.6 ± 2.55-5.8 ± 2.54-5.5 ± 2.33
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference (final values): -2.0 · 95% CI -3.0 to -1.0
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference (final values): -2.8 · 95% CI -3.8 to -1.8
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference (final values): -2.3 · 95% CI -3.3 to -1.3
SecondaryAbsolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24

Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For average itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

Time frame:
Baseline to Week 24
Reported as:
Mean · units on a scale
Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24
units on a scalePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 1-0.9 ± 1.24-2.0 ± 1.94-2.3 ± 1.86-1.8 ± 1.64
Week 2-1.2 ± 1.73-3.1 ± 2.32-3.3 ± 1.89-3.3 ± 2.50
Week 4-1.5 ± 1.73-3.5 ± 2.47-4.1 ± 2.16-3.8 ± 2.63
Week 8-2.1 ± 1.95-4.1 ± 2.42-4.9 ± 2.13-4.7 ± 2.39
Week 12-2.4 ± 2.43-4.9 ± 2.48-5.5 ± 2.29-4.6 ± 2.50
Week 16-3.0 ± 2.47-5.3 ± 2.18-5.7 ± 2.19-5.1 ± 2.59
Week 20-3.3 ± 2.55-5.3 ± 2.47-5.8 ± 2.18-5.3 ± 2.50
Week 24-3.7 ± 2.59-5.5 ± 2.53-5.6 ± 2.49-5.2 ± 2.19
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference (final values): -1.9 · 95% CI -3.0 to -0.9
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference (final values): -2.6 · 95% CI -3.6 to -1.6
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference (final values): -2.1 · 95% CI -3.1 to -1.1
SecondaryPercentage Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24

Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For average itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.

Time frame:
Baseline to Week 24
Reported as:
Mean · Percentage of change
Percentage Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24
Percentage of changePlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Week 1-11.0 ± 16.33-24.6 ± 23.39-29.4 ± 28.24-23.2 ± 22.63
Week 2-14.6 ± 23.01-39.9 ± 29.89-45.2 ± 25.06-40.4 ± 33.77
Week 4-19.7 ± 22.48-43.5 ± 31.66-55.8 ± 27.60-48.2 ± 33.16
Week 8-26.9 ± 25.34-52.0 ± 29.50-65.1 ± 24.67-61.5 ± 28.03
Week 12-30.9 ± 31.63-61.7 ± 30.02-72.2 ± 25.36-60.1 ± 29.77
Week 16-40.2 ± 31.73-66.8 ± 27.02-73.9 ± 22.83-67.1 ± 31.64
Week 20-42.7 ± 32.43-67.5 ± 30.03-74.5 ± 24.85-70.6 ± 29.39
Week 24-47.7 ± 32.60-68.7 ± 30.60-69.9 ± 35.76-70.5 ± 26.41
Statistical analysis
  • Placebo vs Nemolizumab (10 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -23.8 · 95% CI -37.7 to -9.9
  • Placebo vs Nemolizumab (30 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -31.4 · 95% CI -45.0 to -17.7
  • Placebo vs Nemolizumab (90 mg) · Kenward Roger · p = <0.001 · Mean difference of percentage changes: -29.2 · 95% CI -43.2 to -15.2

Adverse events

Collected over From screening to Follow-up visit (Week 32)/Early termination visit. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/56 (0%)1/56 (1.8%)43/56 (76.8%)
Nemolizumab (10 mg)1/55 (1.8%)3/55 (5.5%)47/55 (85.5%)
Nemolizumab (30 mg)0/57 (0%)2/57 (3.5%)47/57 (82.5%)
Nemolizumab (90 mg)0/57 (0%)2/57 (3.5%)47/57 (82.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
Staphylococcal sepsisInfections and infestations0/561/550/570/57
Dermatitis atopicSkin and subcutaneous tissue disorders0/561/551/570/57
Cardio-respiratory arrestCardiac disorders0/561/550/570/57
AstheniaGeneral disorders0/561/550/570/57
Post-traumatic amnestic disorderPsychiatric disorders0/561/550/570/57
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/561/550/570/57
HypertensionVascular disorders1/560/550/570/57
CellulitisInfections and infestations0/560/551/570/57
Septic shockInfections and infestations0/560/550/571/57
Urinary tract infectionInfections and infestations0/560/550/571/57
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)
NasopharyngitisInfections and infestations12/5618/5514/5713/57
Dermatitis atopicSkin and subcutaneous tissue disorders18/5611/5513/5716/57
AsthmaRespiratory, thoracic and mediastinal disorders1/562/557/5710/57
HeadacheNervous system disorders7/567/554/575/57
Upper respiratory tract infectionInfections and infestations1/564/556/574/57
SinusitisInfections and infestations0/564/553/571/57
NauseaGastrointestinal disorders3/564/551/571/57
Blood creatine phosphokinase increasedInvestigations4/562/551/571/57
GastroenteritisInfections and infestations1/560/553/574/57
Urinary tract infectionInfections and infestations3/563/551/571/57

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants. The ITT population was analyzed according to the treatment groups or stratum assigned at randomization.

Age, Categorical
Age, Categorical(Participants)PlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)Total
<=18 years00000
Between 18 and 65 years54535151209
>=65 years326617
Age, Continuous
Age, Continuous(years)PlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)Total
Mean40.9 ± 15.0135.3 ± 14.8340.2 ± 16.6440.9 ± 14.9539.3 ± 15.45
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)Total
Female26262831111
Male31292926115
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)Total
American Indian or Alaska Native01001
Asian4116425
Native Hawaiian or Other Pacific Islander00000
Black or African American8310829
White45384044167
More than one race00000
Unknown or Not Reported02114
Height
Height(centimetre)PlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)Total
Mean170.0 ± 10.28169.7 ± 8.98171.5 ± 8.55170.6 ± 9.94170.5 ± 9.43
Weight
Weight(kilogram)PlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)Total
Mean80.58 ± 18.83573.72 ± 14.62976.90 ± 18.61380.49 ± 22.77077.96 ± 19.052
Body mass index
Body mass index(kilogram per square metre)PlaceboNemolizumab (10 mg)Nemolizumab (30 mg)Nemolizumab (90 mg)Total
Mean27.79 ± 5.63825.54 ± 4.42926.18 ± 6.37027.51 ± 6.69426.77 ± 5.894
08

Study locations

67 sites
  • Galderma Investigational site
    Birmingham, Alabama 35209, United States
  • Galderma Investigational site
    Fort Smith, Arkansas 72916, United States
  • Galderma Investigational site
    Beverly Hills, California 90212, United States
  • Galderma Investigational site
    Fountain Valley, California 92708, United States
  • Galderma Investigational site
    Fremont, California 94538, United States
  • Galderma Investigational site
    Rolling Hills Estates, California 90274, United States
  • Galderma Investigational site
    Santa Ana, California 92701, United States
  • Galderma Investigational site
    Santa Monica, California 90404, United States
  • Galderma Investigational site
    Miami, Florida 33135, United States
  • Galderma Investigational site
    Tampa, Florida 33607, United States
  • Galderma Investigational Site
    Tampa, Florida 33624, United States
  • Galderma Investigational site
    Columbus, Georgia 31904, United States
  • Galderma Investigational site
    Sandy Springs, Georgia 30328, United States
  • Galderma Investigational Site
    Darien, Illinois 60561, United States
  • Galderma Investigational Site
    Overland Park, Kansas 66215, United States
  • Galderma Investigational site
    New Orleans, Louisiana 70115, United States
  • Galderma Investigational Site
    Farmington Hills, Michigan 78334, United States
  • Galderma Investigational site
    Forest Hills, New York 11375, United States
  • Galderma Investigational site
    New York, New York 10025, United States
  • Galderma Investigational Site
    New York, New York 10075, United States
  • Galderma Investigational site
    Chapel Hill, North Carolina 27516, United States
  • Galderma Investigational Site
    Johnston, Rhode Island 02919, United States
  • Galderma Investigational site
    Dallas, Texas 75230, United States
  • Galderma Investigational site
    San Antonio, Texas 78218, United States
  • Galderma Investigational Site
    Waco, Texas 76710, United States
  • Galderma Investigational site
    Richmond, Virginia 23220, United States
  • Galderma Investigational Site
    Benowa, 4217 QLD, Australia
  • Galderma Investigational Site
    Kogarah, NSW 2217, Australia
  • Galderma Investigational Site
    Melbourne, VIC3002, Australia
  • Galderma Investigational Site
    Phillip, ACT2606, Australia
  • Galderma Investigational Site
    Calgary, AB T3A 2N1, Canada
  • Galderma Investigational Site
    Markham, ON L3P 1X2, Canada
  • Galderma Investigational Site
    Oakville, ON L6J 7W5, Canada
  • Galderma Investigational Site
    Ottawa, K1G 6C6, Canada
  • Galderma Investigational Site
    Ottawa, ON K2G 6E2, Canada
  • Galderma Investigational Site
    Peterborough, K9J, Canada
  • Galderma Investigational Site
    Richmond Hill, ON L4C, Canada
  • Galderma Investigational Site
    Sainte-Foy, QC G1V4X7, Canada
  • Galderma Investigational Site
    Waterloo, ON N2J 1C4, Canada
  • Galderma Investigational Site
    Bordeaux, 33075, France
  • Galderma Investigational Site
    Lille, 59037, France
  • Galderma Investigational Site
    Marseille, 13385, France
  • Galderma Investigational Site
    Nice, 06202, France
  • Galderma Investigational Site
    Paris, 75010, France
  • Galderma Investigational Site
    Toulouse, 31059, France
  • Galderma Investigational Site
    Berlin, 10117, Germany
  • Galderma Investigational Site
    Berlin, 10789, Germany
  • Galderma Investigational Site
    Darmstadt, 64283, Germany
  • Galderma Investigational Site
    Erlangen, 91054, Germany
  • Galderma Investigational Site
    Frankfurt, 60590, Germany
  • Galderma Investigational Site
    Hamburg, 20354, Germany
  • Galderma Investigational Site
    Hannöver, 30625, Germany
  • Galderma Investigational Site
    Heidelberg, 69120, Germany
  • Galderma Investigational Site
    Langenau, 89129, Germany
  • Galderma Investigational Site
    Mainz, 55131, Germany
  • Galderma Investigational Site
    München, 80337, Germany
  • Galderma Investigational Site
    Osnabrück, 49074, Germany
  • Galderma Investigational Site
    Stuttgart, 70718, Germany
  • Galderma Investigational Site
    Katowice, 40-123, Poland
  • Galderma Investigational Site
    Katowice, 40-648, Poland
  • Galderma Investigational Site
    Kraków, 31-024, Poland
  • Galderma Investigational Site
    Lublin, 20-080, Poland
  • Galderma Investigational Site
    Warsaw, 01-817, Poland
  • Galderma Investigational Site
    Warsaw, 02-625, Poland
  • Galderma Investigational Site
    Warsaw, 02-758, Poland
  • Galderma Investigational Site
    Wrocław, 51-318, Poland
  • Galderma Investigational Site
    Łódź, 90-436, Poland
09

References and documents

Publications

  • Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, Murrell DF, Alexis A, Lindsey L, Ahmad F, Piketty C, Clucas A. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020 Jan;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013. Epub 2019 Aug 23. PubMed 31449914 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jul 2018, 13 months.

Results were first posted in Oct 2019, 1 year 3 months after primary completion.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2017
First posted
Apr 4, 2017
StartActual
Jun 14, 2017
Primary completionActual
Jul 19, 2018
CompletionActual
Sep 21, 2018
Results first posted
Oct 22, 2019
Last update
Oct 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03100344
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Jun 14, 2017
Primary completion
Jul 19, 2018
Completion
Sep 21, 2018
Results posted
Oct 22, 2019
Last update
Oct 22, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion